<SEC-DOCUMENT>0001144204-19-000236.txt : 20190103
<SEC-HEADER>0001144204-19-000236.hdr.sgml : 20190103
<ACCEPTANCE-DATETIME>20190103070515
ACCESSION NUMBER:		0001144204-19-000236
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190103
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190103
DATE AS OF CHANGE:		20190103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		19503612

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv510242_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
January 3, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8.01. Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 3, 2019, Synthetic Biologics,
Inc. (the &ldquo;Company&rdquo;) issued a press release announcing that the first two patients have been enrolled in the SYN-010 Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin
lactone designed to reduce methane production by certain microorganisms (<I>M. smithii</I>) in the gut to treat an underlying cause
of irritable bowel syndrome with constipation (IBS-C). Cedars-Sinai Medical Center and Synthetic Biologics are co-funding the study,
which will further assess the efficacy and safety of SYN-010 in patients diagnosed with IBS-C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The press release attached as Exhibit 99.1
to this Current Report on Form 8-K, which is incorporated herein by reference, includes &ldquo;safe harbor&rdquo; language pursuant
to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the press
release are &ldquo;forward-looking&rdquo; rather than historical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company undertakes no duty or obligation
to update or revise information included in this Current Report on Form 8-K or the press release attached as Exhibit 99.1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="padding: 0; text-indent: 0; width: 10%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 88%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Exhibit<BR>
        No.</B></P></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-align: center; text-indent: 0"><A HREF="tv510242_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><A HREF="tv510242_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release issued by Synthetic Biologics, Inc. dated January 3, 2019</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 8pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: January 3, 2019</FONT></TD>
    <TD STYLE="padding-bottom: 8pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 1.65pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 2.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid; padding-right: 3.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 2.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 3.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 2.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: 4.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%; border-bottom: black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><A HREF="tv510242_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1&nbsp;</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv510242_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release issued by Synthetic Biologics, Inc. dated January 3, 2019</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv510242_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Announces First
Two Patients Enrolled in Phase 2b Investigator-Sponsored </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Clinical Study of SYN-010, for the Treatment
of IBS-C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, January 03, 2019 &ndash;
</B><U>Synthetic Biologics, Inc.</U> (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve
the microbiome to protect and restore the health of patients, today announced that the first two patients have been enrolled in
SYN-010&rsquo;s Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin
lactone designed to reduce methane production by certain microorganisms (<I>M. smithii) </I>in the gut to treat an underlying
cause of irritable bowel syndrome with constipation (IBS-C). Cedars-Sinai Medical Center (CSMC) and Synthetic Biologics are co-funding
the study, which will further assess the efficacy and safety of SYN-010 in patients diagnosed with IBS-C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;IBS with constipation can be debilitating
for millions of people worldwide, and this study will go a long way toward helping identify whether SYN-010 can become a valuable
tool in addressing the underlying causes and offering relief to those patients,&rdquo; said Mark Pimentel, M.D., head of the Pimentel
Laboratory and executive director of the Medically Associated Science and Technology (MAST) Program at CSMC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase 2b study is beng conducted by
the MAST Program at CSMC and comprises a 12-week, placebo-controlled, double-blind, randomized clinical trial to evaluate two dose
strengths of oral SYN-010 (21 mg and 42 mg) in approximately 150 patients diagnosed with IBS-C. A data readout from this investigator-sponsored
clinical study is expected during the second half of 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are very excited to begin enrollment
of our SYN-010 Phase 2b investigator-sponsored clinical study,&rdquo; said Steven A. Shallcross, Chief Executive Officer of Synthetic
Biologics. &ldquo;SYN-010 remains an integral component in our portfolio of microbiome-focused assets and represents a promising
and differentiated approach to treating the underlying cause of the symptoms commonly associated with IBS-C. This study will be
instrumental in our efforts to expand and fortify the already well-established dataset for SYN-010 and may help determine the optimal
dose strength of SYN-010 for potential future registration studies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary objective for the study will
be to determine the efficacy of SYN-010, measured as an improvement from baseline in the weekly average number of complete spontaneous
bowel movements (CSBMs) during the 12-week treatment period for SYN-010 21 mg and 42 mg daily doses relative to placebo. Secondary
efficacy endpoints for both dose strengths of SYN-010 are expected to measure changes from baseline in abdominal pain, bloating,
stool frequency as well as the use of rescue medication relative to placebo. Exploratory outcomes include Adequate Relief and quality
of life measures using the well-validated EQ-5D-5L and PAC-SYM patient questionnaires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent rights covering the use of SYN-010
are owned by Cedars-Sinai Medical Center and are exclusively licensed by Cedars-Sinai Medical Center to Synthetic Biologics. Both
Cedars-Sinai and Dr. Pimentel have a financial interest in Synthetic Biologics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Irritable Bowel Syndrome</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IBS affects an estimated 10 to 15 percent
of the population, or as many as 45 million people in North America. The illness affects both men and women; however, two-thirds
of diagnosed sufferers are women. It has been reported that up to 20 percent of all IBS patients have IBS-C and current FDA-approved
therapies for the treatment of IBS-C, which include prescription and over-the-counter laxatives, do little to treat the underlying
cause of the disease. These products provide patients with temporary relief from the symptoms of constipation by elevating the
amount of water which passes through the gastrointestinal tract, but tend to cause an IBS-C patient to swing from suffering from
constipation, to suffering from diarrhea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About SYN-010</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-010 is a proprietary, modified-release
formulation of lovastatin lactone that is intended to reduce methane production by certain microorganisms (<I>M. smithii</I>)
in the gut while minimizing disruption to the microbiome to treat an underlying cause of IBS-C. SYN-010 is intended to act primarily
in the intestinal lumen while avoiding systemic absorption, thereby targeting a major cause of IBS-C, not just the symptoms. To
learn more about SYN-010&rsquo;s unique mechanism of action, please <U>click here</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cedars-Sinai Medical Center</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cedars-Sinai is a national leader in providing
high-quality, patient-centered healthcare encompassing primary care as well as specialized medicine and conducting research that
leads to lifesaving discoveries and innovations. Since its beginning in 1902, Cedars-Sinai has evolved to meet the healthcare needs
of one of the most diverse regions in the nation, continually setting new standards in quality and innovation in patient care,
research, teaching and community service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today, Cedars-Sinai is widely known for
its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai impacts the future of healthcare globally
by developing new approaches to treatment and educating tomorrow's physicians and other health professionals. At the same time,
Cedars-Sinai demonstrates a longstanding commitment to strengthening the Los Angeles community through wide-ranging programs that
improve the health of its most vulnerable residents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American:
SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of
patients. The Company's lead late-stage candidates are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome
from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics to prevent microbiome damage, <I>C. difficile
</I>infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which
is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable
bowel syndrome with constipation (IBS-C). The Company&rsquo;s preclinical pursuits include an oral formulation of the enzyme intestinal
alkaline phosphatase (IAP) to treat both local GI and systemic diseases as well as monoclonal antibody therapies for the prevention
and treatment of pertussis. For more information, please visit Synthetic Biologics' website at <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>www.syntheticbiologics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements
can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions,
and includes statements regarding SYN-010 representing a promising and differentiated approach to treating the underlying cause
of the symptoms commonly associated with IBS-C, potential future registration studies, the planned design of the Phase 2b study,
the expected data readout from this investigator-sponsored clinical study during the second half of 2019, the potential of SYN-010
to treat the cause of IBS-C not just the symptoms and the study helping to determine the optimal dose strength of SYN-010 for potential
future registration studies. These forward-looking statements are based on management's expectations and assumptions as of the
date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that
could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include,
among others, the ability to received Institutional Board Approval of the Phase 2b trial protocol, the ability to commence the
trial when anticipated, the results of the SYN-010 trial demonstrating support for the use of SYN-010 to treat symptoms of IBS-C,
Synthetic Biologics' ability to regain compliance with the continued listing standards of the NYSE American by September 2, 2019,
Synthetic Biologics' ability to comply with other continued listing requirements of the NYSE American, the ability of its product
candidates to demonstrate safety and effectiveness, as well as results that are consistent with prior results, Synthetic Biologics'
clinical trials continuing enrollment as expected, a failure to receive the necessary regulatory approvals for commercialization
of Synthetic Biologics' therapeutics, including approval of proposed trial designs, a failure of Synthetic Biologics' clinical
trials, and those conducted by investigators, for SYN-004 and SYN-010 to be commenced or completed on time or to achieve desired
results and benefits, a failure of Synthetic Biologics' clinical trials to continue enrollment as expected or receive anticipated
funding, a failure of Synthetic Biologics to successfully develop, market or sell its products, Synthetic Biologics' inability
to maintain its material licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize
products, Synthetic Biologics&rsquo; ability to achieve acceptance of its product candidates in the marketplace and the successful
development, marketing or sale of Synthetic Biologics' products by competitors that render Synthetic Biologics' products obsolete
or non-competitive, the continued maintenance and growth of Synthetic Biologics' patent estate, Synthetic Biologics becoming and
remaining profitable, Synthetic Biologics' ability to obtain or maintain the capital or grants necessary to fund its research and
development activities, a loss of any of Synthetic Biologics' key scientists or management personnel and other factors described
in Synthetic Biologics' Form 10-K for the year ended December 31, 2017 and its other filings with the SEC, including subsequent
periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and Synthetic
Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information,
future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director, Corporate Communication, (240)
660-2000, <U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cedars-Sinai</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jonathan Diamond, Senior Communications Specialist, (323) 866-8146,
<U>jonathan.diamond@cshs.org</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@ogilvy.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !1 1T# 2(  A$! Q$!_\0
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M=I9>+9]UQK'A_<0D7]L2*#+JVD(<+)=N'U.R3,DCWL";(O[N\ _VAN XGS'
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M@?)X\,9MPJZV9U,#GD\=6S/&5\9"MF>)Q.8U<!5Q6)>)^IT:$*LGEN#A"-+
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MSO.L!5S/#XFO5I8ZM4Q/$&8T<6O]FHXC"3IT52HRBZS^ _V<OAU^V%J'QO\
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MPA"$4W:,(0BDHPC&)1115$A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
